Inherited DNA deletions and duplications and aggressive prostate cancer risk in men of African and European ancestry
Contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestry
This project looks at whether inherited DNA deletions and duplications raise the chance of aggressive prostate cancer in men of African and European ancestry.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11269171 on NIH RePORTER |
What this research studies
You would be contributing to research that examines inherited DNA deletions and duplications known as copy number variations (CNVs) to see if they increase the risk of aggressive prostate cancer. The team will combine existing genetic data from large studies (genome-wide arrays, whole-exome and whole-genome sequencing) with advanced detection methods to find CNVs across sizes and frequencies. They will compare CNV patterns between men with aggressive prostate cancer and men without cancer, with a special focus on men of African and European ancestry. The goal is to find genetic markers that help explain who is more likely to develop dangerous prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates are men of African or European ancestry who have been diagnosed with aggressive prostate cancer or men without prostate cancer who can provide genetic samples and health information.
Not a fit: People unlikely to receive direct benefit include individuals not of African or European ancestry and patients already receiving end-stage treatments where genetic risk findings would not change immediate care.
Why it matters
Potential benefit: If successful, this work could identify genetic markers that improve risk prediction and guide earlier screening or prevention for men at higher risk of aggressive prostate cancer.
How similar studies have performed: Large genome-wide studies have found many single-letter DNA variants linked to prostate cancer, but germline CNVs have been less studied and this combined imputation-plus-sequencing approach for aggressive disease in diverse populations is relatively new.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Chen, Fei — University of Southern California
- Study coordinator: Chen, Fei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.